sma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; felbamate is a weak inducer of CYP3A4.
Felodipine: Use caution when administering velpatasvir with felodipine. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); felodipine is an inhibitor of P-gp.
Flibanserin: Use caution when administering velpatasvir with flibanserin. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); flibanserin is an inhibitor of P-gp.
Fluconazole: Use caution when administering velpatasvir with fluconazole. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Fluconazole is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Fluoxetine: Use caution when administering velpatasvir with fluoxetine. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Fluoxetine is a weak CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Fluoxetine; Olanzapine: Use caution when administering velpatasvir with fluoxetine. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Fluoxetine is a weak CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Flutamide: Avoid coadministration of velpatasvir with flutamide. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; flutamide is an inducer of CYP3A4.
Fluvoxamine: Use caution when administering velpatasvir with fluvoxamine. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Fluvoxamine is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Fosamprenavir: Avoid coadministration of velpatasvir with fosamprenavir. Taking these drugs together may significantly reduce the plasma concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); fosamprenavir is a P-gp inducer. Velpatasvir is also a substrate for CYP3A4; fosamprenavir is an inducer/inhibitor of CYP34. Caution is advised when administering sofosbuvir with fosamprenavir, as concurrent use may result in reduced sofosbuvir plasma concentrations. Sofosbuvir is a substrate for the drug transporter P-glycoprotein (P-gp). Amprenavir, the active metabolite of fosamprenavir, is a P-gp inducer.
Fosphenytoin: Avoid coadministration of sofosbuvir with fosphenytoin. Taking these drugs together may decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp) and CYP3A4, such as fosphenytoin. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a P-gp and CYP3A4 substrate.
Glimepiride; Pioglitazone: Use caution when administering velpatasvir with pioglitazone. Taking th |
